1
|
Fu S, Hirte H, Welch S, Ilenchuk TT, Lutes T, Rice C, Fields N, Nemet A, Dugourd D, Piha-Paul S, Subbiah V, Liu L, Gong J, Hong D, Stewart JM. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs 2017; 35:397. [PMID: 28389981 PMCID: PMC5443850 DOI: 10.1007/s10637-017-0455-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- S Fu
- Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA
| | - H Hirte
- Juravinski Cancer Centre, Hamilton, ON, Canada
| | - S Welch
- London Health Sciences Centre, London, ON, Canada
| | | | - T Lutes
- Soricimed Biopharma Inc., Moncton, NB, Canada
| | - C Rice
- Soricimed Biopharma Inc., Moncton, NB, Canada
| | - N Fields
- Sagecon Inc., Oakville, ON, Canada
| | - A Nemet
- CLINSIG Research Consulting Inc., Brampton, ON, Canada
| | - D Dugourd
- Soricimed Biopharma Inc., Moncton, NB, Canada
| | - S Piha-Paul
- Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA
| | - V Subbiah
- Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA
| | - L Liu
- Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA
| | - J Gong
- Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA
| | - D Hong
- Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA
| | - J M Stewart
- Soricimed Biopharma Inc., Moncton, NB, Canada.
| |
Collapse
|